Regorafenib in glioblastoma recurrence: A case report.
Cancer Treat Res Commun
; 26: 100263, 2021.
Article
en En
| MEDLINE
| ID: mdl-33338858
ABSTRACT
GBM (glioblastoma multiforme) is the most common and aggressive brain tumor. To date, treatment options for glioblastoma recurrence are lacking. Recently, REGOMA trial showed the superiority of regorafenib to lomustine in patients with first glioblastoma recurrence. We report an excellent response to three months treatment with regorafenib, in a patient who presented a rapid progression after the end of post operative radio-chemotherapy and after only one cycle of adjuvant TMZ (Temozolomide).
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Compuestos de Fenilurea
/
Piridinas
/
Neoplasias Encefálicas
/
Glioblastoma
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Cancer Treat Res Commun
Año:
2021
Tipo del documento:
Article